Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074103564> ?p ?o ?g. }
- W2074103564 endingPage "650" @default.
- W2074103564 startingPage "637" @default.
- W2074103564 abstract "The development of disease-modifying therapies (DMT) in multiple sclerosis (MS) has rapidly evolved over the last few years and continues to do so. Prior to the United States Food and Drug Administration approval of the immunomodulatory agent, interferon-beta1b in 1993, no other drug had been shown to alter the course of the disease in a controlled study of MS. At present, there are five licenced disease-modifying agents in MS - interferon-beta1b, interferon-beta1a, glatiramer acetate, natalizumab and mitoxantrone. All have shown significant therapeutic efficacy in large controlled trials. However, current therapies are only partially effective and are not free from adverse effects. Moreover, available DMTs are overwhelmingly biased in favour of those with relapsing-remitting disease. Effective treatment for progressive MS is severely limited, with only interferon-beta1b and mitoxantrone having licenced use in secondary progressive, but not primary progressive disease. Monoclonal antibodies, such as natalizumab selectively target immune pathways involved in the pathogenic process of MS. Alemtuzumab, daclizumab and rituximab are other notable monoclonal antibodies currently undergoing phase II and III trials in MS. Alemtuzumab has so far shown promising therapeutic benefit in relapsing disease, although immunological adverse effects have been a problem. Oral therapies have the benefit of improved tolerability and patient compliance compared with current parenteral treatments. Cladribine and fingolimod (FTY720) have shown encouraging results in their phase III clinical trials. It is also worth noting the evidence for starting DMT in patients with clinically isolated syndrome, whereby early treatment has shown to delay the onset of clinically definite MS in separate phase III studies." @default.
- W2074103564 created "2016-06-24" @default.
- W2074103564 creator A5055313284 @default.
- W2074103564 creator A5082755259 @default.
- W2074103564 date "2010-04-01" @default.
- W2074103564 modified "2023-09-27" @default.
- W2074103564 title "Current and future disease-modifying therapies in multiple sclerosis" @default.
- W2074103564 cites W121485390 @default.
- W2074103564 cites W1486269303 @default.
- W2074103564 cites W1578741880 @default.
- W2074103564 cites W1593132420 @default.
- W2074103564 cites W1666336517 @default.
- W2074103564 cites W1823172479 @default.
- W2074103564 cites W1915820185 @default.
- W2074103564 cites W1928660309 @default.
- W2074103564 cites W1966718542 @default.
- W2074103564 cites W1975104912 @default.
- W2074103564 cites W1976947891 @default.
- W2074103564 cites W1979811627 @default.
- W2074103564 cites W1981220317 @default.
- W2074103564 cites W1984999645 @default.
- W2074103564 cites W1987790752 @default.
- W2074103564 cites W1992656196 @default.
- W2074103564 cites W1994630947 @default.
- W2074103564 cites W1996481500 @default.
- W2074103564 cites W1997510964 @default.
- W2074103564 cites W1998000193 @default.
- W2074103564 cites W1999663447 @default.
- W2074103564 cites W2000379621 @default.
- W2074103564 cites W2000443242 @default.
- W2074103564 cites W2001356567 @default.
- W2074103564 cites W2001642942 @default.
- W2074103564 cites W2005506388 @default.
- W2074103564 cites W2012054969 @default.
- W2074103564 cites W2013810114 @default.
- W2074103564 cites W2019582599 @default.
- W2074103564 cites W2020047554 @default.
- W2074103564 cites W2023211244 @default.
- W2074103564 cites W2024898420 @default.
- W2074103564 cites W2029012161 @default.
- W2074103564 cites W2030830834 @default.
- W2074103564 cites W2031869195 @default.
- W2074103564 cites W2037320008 @default.
- W2074103564 cites W2038211281 @default.
- W2074103564 cites W2038428996 @default.
- W2074103564 cites W2038610301 @default.
- W2074103564 cites W2038611965 @default.
- W2074103564 cites W2039481121 @default.
- W2074103564 cites W2041208157 @default.
- W2074103564 cites W2041686092 @default.
- W2074103564 cites W2044063690 @default.
- W2074103564 cites W2046729196 @default.
- W2074103564 cites W2046941822 @default.
- W2074103564 cites W2049363669 @default.
- W2074103564 cites W2051165446 @default.
- W2074103564 cites W2053683902 @default.
- W2074103564 cites W205599027 @default.
- W2074103564 cites W2056736742 @default.
- W2074103564 cites W2059422242 @default.
- W2074103564 cites W2059736489 @default.
- W2074103564 cites W2063804735 @default.
- W2074103564 cites W2064775943 @default.
- W2074103564 cites W2066919456 @default.
- W2074103564 cites W2070513259 @default.
- W2074103564 cites W2070558858 @default.
- W2074103564 cites W2074090142 @default.
- W2074103564 cites W2074864913 @default.
- W2074103564 cites W2078430285 @default.
- W2074103564 cites W2078775078 @default.
- W2074103564 cites W2079367120 @default.
- W2074103564 cites W2079441479 @default.
- W2074103564 cites W2082470201 @default.
- W2074103564 cites W2088302755 @default.
- W2074103564 cites W2088950613 @default.
- W2074103564 cites W2095666175 @default.
- W2074103564 cites W2097669496 @default.
- W2074103564 cites W2101674248 @default.
- W2074103564 cites W2102369421 @default.
- W2074103564 cites W2103758700 @default.
- W2074103564 cites W2105026328 @default.
- W2074103564 cites W2106467284 @default.
- W2074103564 cites W2110066995 @default.
- W2074103564 cites W2110477182 @default.
- W2074103564 cites W2112044962 @default.
- W2074103564 cites W2113485611 @default.
- W2074103564 cites W2113754168 @default.
- W2074103564 cites W2115691668 @default.
- W2074103564 cites W2118818657 @default.
- W2074103564 cites W2119172537 @default.
- W2074103564 cites W2119260372 @default.
- W2074103564 cites W2120574509 @default.
- W2074103564 cites W2120793461 @default.
- W2074103564 cites W2121931605 @default.
- W2074103564 cites W2122894564 @default.
- W2074103564 cites W2123069839 @default.
- W2074103564 cites W2124417387 @default.
- W2074103564 cites W2127264662 @default.
- W2074103564 cites W2128402413 @default.